Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Aug 27, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Progress on CAR-T cell therapy for hematological malignancies.

Kejia Hu^1,2,3,4, Yue Huang^1,2,3,4, Yongxian Hu^1,2,3,4

¹1. Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences

|September 26, 2022

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preliminary study of the effect of user intent recognition errors on volitional control of powered lower limb prostheses.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2013

Same author

Promise of a low power mobile CPU based embedded system in artificial leg control.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2013

Same author

An automatic and user-driven training method for locomotion mode recognition for artificial leg control.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2013

Same author

Graphite-supported perchloric acid (HClO4-C): an efficient and recyclable heterogeneous catalyst for the one-pot synthesis of amidoalkyl naphthols.

Molecules (Basel, Switzerland)·2013

Same author

2D correlation analysis: sequential order judging.

Analytical chemistry·2013

Same author

Cofactor engineering through heterologous expression of an NADH oxidase and its impact on metabolic flux redistribution in Klebsiella pneumoniae.

Biotechnology for biofuels·2013

Chimeric antigen receptor (CAR) T cell therapy shows promise for blood cancers. Researchers are developing advanced CAR-T cells, including multi-target and iPSC-derived options, to improve efficacy and reduce side effects for various hematological malignancies.

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T cell therapy is a successful treatment for hematological malignancies.
Specific CAR-T cell types target B lymphoblastic leukemia (CD19), multiple myeloma (BCMA), and T cell malignancies (CD7).
Myeloid malignancies present unique challenges, driving diverse research approaches.

Purpose of the Study:

To review the latest advancements in CAR-T cell therapy for hematological malignancies.
To discuss the development of novel CAR-T cell strategies.
To highlight Chinese contributions to CAR-T cell therapy research and clinical systems.

Main Methods:

Review of current literature on CAR-T cell therapy for hematological malignancies.

Keywords:

Chimeric antigen receptor T cell Gene editing Hematological malignancies Induced pluripotent stem cell Review Universal

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Aug 27, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Discussion of emerging CAR-T cell technologies.

Analysis of progress in B lymphoblastic, T lymphoblastic, and myeloid malignancies.

Main Results:

Established CAR-T cell therapies for specific blood cancers (e.g., CD19, BCMA, CD7).
Development of advanced CAR-T cell designs: multi-target, universal, and induced pluripotent stem cell (iPSC)-derived CAR-T, CAR-NK, and CAR-iMac cells.
Significant progress in overcoming challenges in myeloid malignancy treatment.

Conclusions:

CAR-T cell therapy continues to evolve with innovative approaches.
Future directions include multi-target, universal, and iPSC-derived CAR-related cell therapies for broader applications.
Ongoing research aims to enhance CAR-T cell effectiveness and minimize adverse effects.